NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...

How a new Trump plan could make science ‘a political football’ The NIH is already in turmoil. Billlions of dol ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently ...

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases.

Lawndale Christian Health Center (LCHC) recently announced the planned retirement of current CEO, Bruce E. Miller. Mr. Miller’s career at LCHC began in 1998 when he served as the organization’s Chief ...